Idra-21コグニティブパウダーはAMPA受容体とベンゾチアジアゾール誘導体の正のアロステリックレギュレーターです。 これは、（プラス）-IDRA-21が活性型であるキラル分子です。
IDRA-21は動物実験でどのように振る舞いましたか？
動物の知性を促進する研究では、IDRA-21パウダー学習能力と記憶力が大幅に向上しました。 アルプラゾラムまたはスコポラミンの長期使用によって引き起こされる認知障害を逆転させる場合、アニラセタムよりも約10-30倍強力です。 最も驚くべきことは、その薬物代謝時間です。それは、単回投与後最大48時間持続する持続的な効果を生み出すことが研究されています。 研究者たちは、この効果のメカニズムは、脳シナプス間の長期的な増強を促進することによる可能性が高いと述べています。
向知性薬の探索のプロセスは何ですか？ どうでしたかIDRA-21生まれ？
In 1990, neuroscientist Eric Kandel discovered a brain chemical called cyclic adenosine monophosphate response element-binding protein (CREB), which is a key factor in memory formation. In 1994, neuroscientists Tim Tully and Jerry Yin adjusted the way CREB works in a fruit fly. When learning new habits, fruit flies with enhanced CREB were 10 times faster than their unchanged counterparts. Later, other researchers got the same results in mice. In 1999, Qian Zhuo, a neuroscientist at Princeton University, created a mouse with more pairs of NR2B genes, which can coordinate the activity of synaptic receptors in the brain. In memory and learning tests, NR2B enhanced mice performed five times better than unmodified mice. After 2000, many new pharmaceutical companies competed to apply these findings to humans. Both memory pharmaceutical and helikongshan medical are conducting clinical trials of drugs related to CREB. Another COLTEX pharmaceutical company is developing a brain chemical called ampakine to achieve similar effects through another neural pathway. Among so many research institutions, Jingsi pharmaceutical （Abbreviation: IDRA） has developed IDRA-21 through step-by-step analogy research. At the same time, there are many sister products of this product, which have been eliminated for various reasons.